Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04233749 · ClinicalTrials.gov registry record · Phase 2
The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans
A Phase 2 study of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT04233749 is a Phase 2 study of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 5 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04233749, a Phase 2 study of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
There are currently no effective treatments for lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP). Tranexamic acid, which may downregulate pigmentation through a reduction in plasmin, has been shown to decrease pigmentation in patients with melasma, another pigmentary disorder. Given that LPP, EDP, and melasma are all disorders of pigmentation with dermal involvement, it is possible that tranexamic acid can also reduce pigmentation in LPP and EDP as well.
Conditions Studied
Interventions
- DRUG Tranexamic acid tablets
Study Locations (1)
Michigan
- New Center One - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-03-17 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04233749
The ClinicalTrials.gov registry entry for NCT04233749 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lichen Planus Pigmentosus appearing as the primary indexed condition, and to 1 intervention - of which Tranexamic acid tablets is the first listed.
NCT04233749 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT04233749 about?
NCT04233749 is a clinical study titled "The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans". There are currently no effective treatments for lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP). Tranexamic acid, which may downregulate pigmentation through a reduction in plasmin, has been shown to decrease pigmentation in patients with melasma, another pigmentary disorder...
What is the current status of trial NCT04233749?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2020-03-17. Estimated completion is 2025-12-30.
What conditions does trial NCT04233749 study?
This clinical trial studies the following conditions: Lichen Planus Pigmentosus, Erythema Dyschromicum Perstans, Ashy Dermatosis of Ramirez.
What interventions are being tested in trial NCT04233749?
The interventions under investigation include: Tranexamic acid tablets (DRUG).
Who is sponsoring clinical trial NCT04233749?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04233749 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.